Lavrador José Pedro, Marchi Francesco, Elhag Ali, Kalyal Nida, Mthunzi Engelbert, Awan Mariam, Wroe-Wright Oliver, Díaz-Baamonde Alba, Mirallave-Pescador Ana, Reisz Zita, Gullan Richard, Vergani Francesco, Ashkan Keyoumars, Bhangoo Ranjeev
Department of Neurosurgery, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
Department of Neurosurgery, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, 6900 Lugano, Switzerland.
Biomedicines. 2024 Nov 30;12(12):2748. doi: 10.3390/biomedicines12122748.
BACKGROUND/OBJECTIVES: 5-aminulevulinic acid (5-ALA)-guided surgery for high-grade gliomas remains a challenge in neuro-oncological surgery. Inconsistent fluorescence visualisation, subjective quantification and false negatives due to blood, haemostatic agents or optical impediments from the external light source are some of the limitations of the present technology.
The preliminary results from this single-centre retrospective study are presented from the first 35 patients operated upon with the novel Nico Myriad Spectra System©. The microdebrider (Myriad) with an additional in situ light system (Spectra) can alternately provide white and blue light (405 nm) to within 15 mm of the tissue surface to enhance the morphology of the anatomical structures and the fluorescence of the pathological tissues.
A total of 35 patients were operated upon with this new technology. Eight patients (22.85%) underwent tubular retractor-assisted minimally invasive parafascicular surgery (tr-MIPS). The majority had high-grade gliomas (68.57%). Fluorescence was identified in 30 cases (85.71%), with residual fluorescence in 11 (36.66%). The main applications were better white-blue light alternation and visualisation during tr-MIPS, increase in the extent of resection at the border of the cavity, identification of satellite lesions in multifocal pathology, the differentiation between radionecrosis and tumour recurrence in redo surgery and the demarcation between normal ependyma versus pathological ependyma in tumours infiltrating the subventricular zone.
This proof-of-concept study confirms that the novel in situ light-source delivery technology integrated with the usual intraoperative armamentarium provides a spatially, functionally and oncologically informed framework for glioblastoma surgery. It allows for the enhancement of the morphology of anatomical structures and the fluorescence of pathological tissues, increasing the extent of resection and, possibly, the prognosis for patients with high-grade gliomas.
背景/目的:5-氨基酮戊酸(5-ALA)引导下的高级别胶质瘤手术仍是神经肿瘤外科手术中的一项挑战。荧光可视化不一致、主观量化以及血液、止血剂或外部光源造成的光学阻碍导致的假阴性是当前技术的一些局限性。
本单中心回顾性研究展示了使用新型Nico Myriad Spectra System©对首批35例患者进行手术的初步结果。带有额外原位照明系统(Spectra)的微型清创器(Myriad)可在组织表面15毫米范围内交替提供白光和蓝光(405纳米),以增强解剖结构的形态和病理组织的荧光。
共有35例患者接受了这项新技术手术。8例患者(22.85%)接受了管状牵开器辅助的微创束旁手术(tr-MIPS)。大多数患者患有高级别胶质瘤(68.57%)。30例(85.71%)发现有荧光,11例(36.66%)有残留荧光。主要应用包括tr-MIPS期间更好的白光-蓝光交替和可视化、增加腔隙边界处的切除范围、识别多灶性病变中的卫星病灶、在再次手术中区分放射性坏死和肿瘤复发以及区分侵犯脑室下区肿瘤中的正常室管膜与病理室管膜。
这项概念验证研究证实,与常规术中设备集成的新型原位光源输送技术为胶质母细胞瘤手术提供了一个在空间、功能和肿瘤学方面具有参考价值的框架。它能够增强解剖结构的形态和病理组织的荧光,增加切除范围,并可能改善高级别胶质瘤患者的预后。